Verrica Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview

Verrica Pharmaceuticals

06/11/2024 14:20

* Verrica Pharmaceuticals Inc  VRCA.OQ   VRCA.O  is expected
to show a rise in quarterly revenue when it reports  results 
for the period ending December 31 2024
    * The West Chester Pennsylvania-based  company is expected
to
report a 202.0% increase in revenue to $6.004 million from $1.99
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Verrica Pharmaceuticals
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 8.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $8.50​, above​ its last closing price
of $0.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.39       -0.37      -0.49     Missed  -33.5
 Jun. 30 2024  -0.43       -0.42      -0.37     Beat    12.9
 Mar. 31 2024  -0.46       -0.40      -0.44     Missed  -10.9​
 Jan. 1 0001   -0.53       -0.53      -0.53     Met     -0.4
 ​​Sep.        -0.35       -0.36      -0.54     Missed  -49.5
 30 2023                                                
 Jun. 30 2023  -0.22       -0.21      -0.24     Missed  -14.2​
 Jan. 1 0001   -0.18       -0.19      -0.15     Beat    21.1
 Jan. 1 0001   -0.19       -0.19      -0.14     Beat    27.3
 This summary was machine generated November 6 at 14:20 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)